Jan 22, 2018 Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARĪ± Agonist
Jan 8, 2018 Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms
Jan 2, 2018 Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARĪ± Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients
Dec 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients
Dec 10, 2017 Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination Approach
Dec 7, 2017 Syros Presents New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, and Discovery of Potential New Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium
Nov 13, 2017 Syros to Present New Preclinical Data on SY-1365 and on Identification of Potential Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium
